Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms
Authors:
- Mohsen Karami FathMFMohsen Karami Fath
- Kimiya BabakhaniyanKBKimiya Babakhaniyan
- Mehran AnjomroozMAMehran Anjomrooz
- Mohammadrasoul JalalifarMJMohammadrasoul Jalalifar
- Seyed Danial AlizadehSASeyed Danial Alizadeh
- Zeinab PourghasemZPZeinab Pourghasem
- Parisa Abbasi OshaghPOParisa Abbasi Oshagh
- Ali AzargoonjahromiAAAli Azargoonjahromi
- Faezeh AlmasiFAFaezeh Almasi
- Hafza Zahira ManzoorHMHafza Zahira Manzoor
- Bahman KhalesiBKBahman Khalesi
- Navid PourzardoshtNPNavid Pourzardosht
Open Access
Abstract
Glioblastoma (GBM) is the most typical and aggressive form of primary brain tumor in adults, with a poor prognosis. Successful glioma treatment is hampered by ineffective medication distribution across the blood-brain barrier (BBB) and the emergence of drug resistance. Although a few FDA-approved multimodal treatments are available for glioblastoma, most patients still have poor prognoses. Targeting epigenetic variables, immunotherapy, gene therapy, and different vaccine- and peptide-based treatments are some innovative approaches to improve anti-glioma treatment efficacy. Following the identification of lymphatics in the central nervous system, immunotherapy offers a potential method with the potency to permeate the blood-brain barrier. This review will discuss the rationale, tactics, benefits, and drawbacks of current glioma therapy options in clinical and preclinical investigations.Keywords
This publication has 363 references indexed in Scilit:
- Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastomaCancer Immunology, Immunotherapy, 2013
- Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastomaCancer Immunology, Immunotherapy, 2012
- A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant gliomaJournal of Clinical Neuroscience, 2011
- Optimization of Cellular Activity of G9a Inhibitors 7-Aminoalkoxy-quinazolinesJournal of Medicinal Chemistry, 2011
- Constitutional tandem duplication of 9q34 that truncates EHMT1 in a child with gangliogliomaPediatric Blood & Cancer, 2011
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of GliomaCancer Cell, 2010
- The prognostic IDH1 R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastomaActa Neuropathologica, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Genetically engineered T cells to target EGFRvIII expressing glioblastomaJournal of Neuro-Oncology, 2009